Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels

Rhea-AI Summary

Humacyte (Nasdaq: HUMA) said the FY2026 U.S. Department of Defense appropriations include targeted funding to support procurement and evaluation of biologic vascular repair technologies for traumatic extremity arterial injuries when autologous vein grafting is not feasible.

Symvess is described as the only human-derived bioengineered blood vessel approved by the FDA; the release highlights a retrospective battlefield study of 16 patients with 100% survival, zero amputations, and zero conduit infections. Safety risks, including graft rupture, anastomotic failure, and thrombosis, are noted with boxed warning language and recommended antiplatelet therapy.

Positive

• FY2026 DoD funding designated to procure biologic vascular repair technologies
• Symvess identified as the only human-derived FDA-approved bioengineered vessel
• Retrospective battlefield study: 16 patients, 100% survival, zero amputations, zero infections

Negative

• Boxed warning: graft failure can cause life-threatening hemorrhage
• Thrombosis is a common adverse reaction (≥10%) requiring antiplatelet therapy
• Symvess is investigational for uses beyond the approved extremity vascular trauma indication

News Market Reaction – HUMA

+30.02% 2.4x vol

51 alerts

+30.02% News Effect

+38.9% Peak in 6 hr 2 min

+$57M Valuation Impact

$249M Market Cap

2.4x Rel. Volume

On the day this news was published, HUMA gained 30.02%, reflecting a significant positive market reaction. Argus tracked a peak move of +38.9% during that session. Our momentum scanner triggered 51 alerts that day, indicating high trading interest and price volatility. This price movement added approximately $57M to the company's valuation, bringing the market cap to $249M at that time. Trading volume was elevated at 2.4x the daily average, suggesting notable buying interest.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Ukraine trauma patients: 16 patients Survival rate: 100% survival Amputation rate: Zero amputations +5 more

8 metrics

Ukraine trauma patients 16 patients Retrospective observational wartime injury study with Symvess

Survival rate 100% survival 16 Ukrainian wartime trauma patients treated with Symvess

Amputation rate Zero amputations Retrospective Symvess wartime trauma cohort

Conduit infections Zero conduit infections 16-patient wartime Symvess study in Ukraine

Anastomotic failure window First 36 days post-implantation Clinical studies monitoring anastomotic failure

Common adverse reactions ≥10% incidence Vascular graft thrombosis, pyrexia and pain with Symvess

Fiscal year FY 2026 DoD Appropriations Act including funding for biologic repair tech

NDAA year FY2026 NDAA Defense law urging integration of breakthrough vascular repair technologies

Market Reality Check

Price: $1.09 Vol: Volume 2,424,336 is 0.57x...

low vol

$1.09 Last Close

Volume Volume 2,424,336 is 0.57x the 20-day average of 4,226,943, indicating no volume spike with the move. low

Technical Shares at 0.9383 trade below the 200-day MA of 1.7 and remain 78.91% under the 52-week high.

Peers on Argus

HUMA gained 5.88% while peers were mixed: IMMP -1.13%, EDIT +2.25%, SLN +3.71%, ...

HUMA gained 5.88% while peers were mixed: IMMP -1.13%, EDIT +2.25%, SLN +3.71%, VOR +6.9%, OABI flat. The move appears stock-specific, not a broad biotech rotation.

Historical Context

5 past events · Latest: Jan 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 08	Health-economic data	Positive	-2.5%	Five-year analysis showed high costs of complications and highlighted Symvess benefits.
Jan 05	Regulatory expansion	Positive	+8.7%	Planned Israel MAA for Symvess with expected 120‑day review leveraging FDA approval.
Dec 22	Clinical results	Positive	-3.6%	Published 36‑month V005 data showing high infection‑free and limb‑salvage rates.
Dec 16	Debt financing	Negative	-5.1%	Announced up to $77.5M term loan with initial $40M used to retire debt.
Nov 20	Clinical presentations	Positive	-4.3%	VEITHsymposium talks reported durable patency, limb salvage, and zero infections.

Pattern Detected

Recent fundamentally positive updates on Symvess often saw mixed to negative next-day moves, especially around clinical data and financing, suggesting a pattern of cautious market reception.

Recent Company History

Over the last few months, Humacyte has highlighted Symvess with clinical and health‑economic data, international expansion plans, and long‑term safety and efficacy results. On Dec 16, 2025, it secured a credit facility and later detailed high hospital charges for arterial injury, positioning Symvess as a potentially cost‑saving option. An Israel MAA was planned for Q1 2026. Despite this progress, several prior positive news days saw share price declines, making today’s DoD‑related funding support notable against a history of mixed price reactions.

Market Pulse Summary

The stock surged +30.0% in the session following this news. A strong positive reaction aligns with t...

Analysis

The stock surged +30.0% in the session following this news. A strong positive reaction aligns with the market’s focus on non-dilutive, government-backed validation for Symvess. Dedicated FY 2026 DoD appropriations and prior NDAA language highlight strategic demand for vascular repair in trauma care. However, shares at 0.9383 remain far below the 4.45 52-week high, and past positive clinical milestones sometimes saw selling. Investors have historically faded good news, so reliance on continued execution and funding remains a key risk factor.

Key Terms

autologous vein harvesting, acellular tissue engineered vessel, antiplatelet therapy, anastomotic failure, +4 more

8 terms

autologous vein harvesting medical

"when autologous vein harvesting is not feasible."

Autologous vein harvesting is the surgical removal of a patient's own vein to use as a replacement blood vessel elsewhere in their body, commonly for bypassing a blocked artery. For investors, it matters because it drives demand for specialized surgical instruments, supplies and training, influences procedure times and complication rates, and affects reimbursement and hospital costs — similar to reusing a homeowner’s own plumbing parts instead of buying new pipes.

acellular tissue engineered vessel medical

"Symvess is an acellular tissue engineered vessel indicated for use in adults"

Acellular tissue engineered vessels are lab-made replacement blood vessels created from biological materials but manufactured without living cells, so they act like a ready-made tube that the body can grow into and line with its own cells. For investors, they matter because they target a steady medical need (for example, replacing or bypassing damaged vessels) and carry commercial upside if proven safe and long-lasting, while also involving manufacturing, clinical trial and regulatory risks.

antiplatelet therapy medical

"preclude long-term antiplatelet therapy (such as aspirin or clopidogrel)"

Antiplatelet therapy uses medicines that make blood platelets less likely to stick together, lowering the chance blood clots will form. Think of platelets as tiny workers or glue patches that seal leaks in blood vessels; these drugs reduce that “glue” to prevent heart attacks, strokes, or clots on medical devices. For investors this matters because safety, trial results, approvals, and prescribing patterns directly affect demand, market size, and regulatory risk for related drugs and devices.

anastomotic failure medical

"Anastomotic failure has occurred in patients treated with Symvess."

Anastomotic failure is when a surgical connection between two bodily structures—most often sections of intestine—is unable to hold and leaks, separates, or closes. For investors, it matters because such failures can increase patient complications, lengthen hospital stays, raise treatment costs, trigger product recalls or lawsuits, and slow or block regulatory approvals and market adoption of surgical devices, materials, or therapies designed to create or protect these joins.

thrombosis medical

"Thrombosis has occurred in patients treated with Symvess."

Thrombosis is the formation of a blood clot inside a blood vessel that can block normal blood flow, like a plaster clogging a pipe. It matters to investors because clotting events affect the safety profile and regulatory review of drugs, medical devices and treatments, can drive costly litigation or recalls, and influence healthcare demand and company valuations tied to patient outcomes and product approvals.

fetal bovine serum medical

"Fetal bovine serum is sourced to minimize the risk of transmitting a prion"

A nutrient-rich liquid taken from the blood of cow fetuses used to grow and maintain cells in laboratory and manufacturing settings. Investors should care because it is a critical raw material for many biologic drugs and diagnostics: shortages, price swings, contamination risks, or moves to animal-free alternatives can affect production costs, regulatory approval, and company valuations much like a factory losing access to a key ingredient.

bovine spongiform encephalopathy medical

"a prion protein that causes bovine spongiform encephalopathy and the cause"

A progressive brain disease of cattle that destroys brain tissue and makes it look spongy, caused by abnormal proteins that steadily damage nerve cells. It matters to investors because outbreaks can force slaughter of herds, halt exports, trigger food recalls and stricter rules, and push up prices or losses across farming, meat processing and related supply chains — similar to how a safety recall can suddenly shrink a product’s market.

variant Creutzfeldt-Jakob disease medical

"and the cause of a rare fatal condition in humans called variant Creutzfeldt-Jakob"

A fatal, rare brain disorder caused by misfolded proteins that progressively destroy brain tissue and function; it develops after exposure to those abnormal proteins and leads to rapidly worsening mental and physical decline. Investors should care because outbreaks or confirmed cases can trigger regulatory action, product recalls, legal liabilities, and shifts in consumer confidence that affect food producers, healthcare providers, insurers, and related industries—similar to how a safety scare can sink demand and raise costs.

AI-generated analysis. Not financial advice.

DURHAM, N.C., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the recently adopted FY 2026 U.S. Department of Defense (DoD) Appropriations Act includes dedicated funding to support the evaluation and incorporation of biologic vascular repair technologies for the warfighters suffering from traumatic vascular injuries.

The FY2026 National Defense Authorization Act (NDAA), enacted in December 2025, stated in report language that DoD should “integrate FDA-approved breakthrough vascular repair technologies in traumatic extremity arterial injury repair, providing an off-the-shelf, biologically active vascular conduit when autologous vein harvesting is not feasible.” In doing so, lawmakers demonstrated that they recognize and understand the need for human-derived bioengineered vessels to save life and limb on the battlefield. Humacyte is grateful to see Congress express even greater support for this medical innovation by designating appropriated funds to advance the goal of making this groundbreaking technology available to service members.

Humacyte’s Symvess® is the only human-derived bioengineered blood vessel approved by the U.S. Food and Drug Administration (FDA).

“America’s brave men and women in uniform deserve the very best care we can provide,” said Laura Niklason, M.D., Ph.D., Founder and Chief Executive Officer of Humacyte. “That’s why, at Humacyte, we are grateful to Congress for directing targeted federal resources for the Department of Defense to acquire biologic vascular repair technology that can be used in combat to treat and repair traumatic vascular injuries in military personnel.”

“This historic, first-of-its-kind federal investment will help ensure our soldiers continue to have access to cutting-edge treatments and state-of-the-art care whenever and wherever they need it,” Niklason continued. “Our product, Symvess, has already been tested on the battlefield in Ukraine, where patients with gunshots, shrapnel, blasts, and accidents were treated as part of a humanitarian program. Sixteen patients from this program followed in a retrospective, observational study had 100% survival, zero amputations and zero conduit infections despite incurring serious wartime injuries. We look forward to working with leaders in our military and the Pentagon to ensure that American service personnel will have access to this same quality of care.”

For uses other than the FDA approval in the extremity vascular trauma indication, Symvess is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

INDICATION

Symvess is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.

IMPORTANT SAFETY INFORMATION

BOXED WARNING: GRAFT FAILURE

Loss of Symvess integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage.

CONTRAINDICATIONS

DO NOT use Symvess in patients who have a medical condition that would preclude long-term antiplatelet therapy (such as aspirin or clopidogrel) after resolution of acute injuries. 

WARNINGS AND PRECAUTIONS

• Graft Rupture
  
  

Vascular graft rupture has occurred in patients treated with Symvess. Advise patients that arterial bleeding can be life-threatening and to seek emergent medical evaluation for any signs or symptoms of graft rupture such as bleeding, pain and swelling in the extremity, or signs of extremity ischemia.

• Anastomotic Failure
  
  

Anastomotic failure has occurred in patients treated with Symvess. In clinical studies of Symvess, anastomotic failure occurred within the first 36 days post-implantation. Monitor patients for signs of anastomotic failure such as pain and swelling at the surgical site, decreasing hemoglobin or other signs and symptoms of bleeding. Advise patients to seek urgent medical evaluation if they have any signs or symptoms that may be indicative of anastomotic failure such as bleeding, swelling or worsening pain at the surgical site or changes in color of overlying skin.

• Thrombosis
  
  

Thrombosis has occurred in patients treated with Symvess. In clinical trials of Symvess, patients received antiplatelet therapy following implantation of Symvess to reduce the risk of thrombosis. The risk of thrombosis may increase in patients who discontinue antiplatelet therapy. Anti-platelet therapy is recommended following treatment with Symvess.

• Transmission of Infectious Diseases
  
  

Symvess is manufactured using cells and reagents that may transmit infectious diseases or infectious agents. The cells used in the manufacture of Symvess are derived from a donor who met the donor eligibility requirements for transmissible infectious diseases which includes screening and testing of risks associated with human immunodeficiency virus 1 (HIV-1), human immunodeficiency virus 2 (HIV-2), hepatitis B virus (HBV), hepatitis C virus (HCV), and syphilis (Treponema pallidum). The cell banks are tested negative for human and animal viruses, retroviruses, bacteria, fungi, yeast, and mycoplasma. While all animal-derived reagents are tested for animal viruses, bacteria, fungi, and mycoplasma before use, these measures do not eliminate the risk of transmitting these or other transmissible infectious diseases and disease agents. Fetal bovine serum is sourced to minimize the risk of transmitting a prion protein that causes bovine spongiform encephalopathy and the cause of a rare fatal condition in humans called variant Creutzfeldt-Jakob disease. No transmissible agent infections have been reported during clinical testing.

ADVERSE REACTIONS

The most common adverse reactions (occurring at ≥ 10%), were vascular graft thrombosis, pyrexia (fever) and pain.

Please see full Prescribing Information at www.symvess.com, including Boxed Warning, for Symvess.

About Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s Biologics License Application for Symvess, the acellular tissue engineered vessel (ATEV), in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

Forward-Looking Statements

This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, our plans and ability to commercialize Symvess and, if approved by regulatory authorities, our product candidates, successfully and on our anticipated timelines; the degree of market acceptance of and the availability of third-party coverage and reimbursement for Symvess and, if approved by regulatory authorities, our product candidates; our ability to manufacture Symvess and, if approved by regulatory authorities, our product candidates in sufficient quantities to satisfy our clinical trial and commercial needs; the anticipated benefits of our ATEVs relative to existing alternatives; our plans and ability to execute product development, process development and preclinical development efforts successfully and on our anticipated timelines; our ability to design, initiate and successfully complete clinical trials and other studies for our product candidates and our plans and expectations regarding our ongoing or planned clinical trials; the anticipated characteristics and performance of our ATEVs; the implementation of our business model and strategic plans for our business; our ability to execute and achieve the expected benefits of our cost-saving measures and whether our efforts will result in further actions or additional asset impairment charges that adversely affect our business; and the timing or likelihood of regulatory filings, acceptances and approvals. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, competitive and/or reputational factors, and other risks and uncertainties, including those described under the header “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 and Form 10-Q for the quarter ended September 30, 2025, each filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com

Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com

FAQ

What funding did the FY2026 DoD Appropriations Act allocate related to Humacyte (HUMA) on February 9, 2026?

It provided targeted appropriations to support evaluation and procurement of biologic vascular repair technologies for traumatic vascular injuries. According to the company, funds are meant to help the Department of Defense acquire off-the-shelf, biologically active vascular conduits when autologous vein grafting is not feasible.

Is Symvess by Humacyte (HUMA) FDA approved and for what indication as of February 9, 2026?

Yes; Symvess is FDA approved as an acellular tissue engineered vessel for extremity arterial injury when autologous vein graft is not feasible. According to the company, the indication covers urgent revascularization to avoid imminent limb loss in adults.

What battlefield clinical outcomes did Humacyte (HUMA) report for Symvess in the retrospective study?

The company reported 16 patients treated with Symvess had 100% survival, zero amputations, and zero conduit infections. According to the company, these outcomes came from a humanitarian program treating wartime injuries such as gunshots, shrapnel, and blast trauma.

What are the main safety warnings investors should note about Symvess (HUMA)?

Symvess carries a boxed warning for graft failure that can cause life-threatening hemorrhage and lists thrombosis risk. According to the company, anastomotic failure occurred within 36 days in studies and antiplatelet therapy is recommended post-implantation.

How might FY2026 DoD procurement funding impact Humacyte's (HUMA) commercial outlook?

The funding could accelerate military adoption and procurement pathways for biologic vascular conduits in trauma care. According to the company, designated funds aim to enable the Department of Defense to acquire FDA-approved vascular repair technology for service members when autologous grafts are not feasible.